– JAPAN, Tokyo – Takeda (TSE:4502 | NYSE: TAK) today announced the nomination of Miki Tsusaka for her election to its Board of Directors at the AGM on June 28th, 2023.
“Takeda is highly committed to advancing the diversity of the Board, including gender, nationalities, skills, and experiences, while ensuring balanced representation of our global stakeholders. With Miki Tsusaka joining our Board, we will be able to strengthen further our governance,” said Masami Iijima, Chair of the Nomination Committee.
CEO Christophe Weber added, “We are very excited to have Miki Tsusaka joining our board. With her deep expertise and experience, we look forward to further pursuing our vision to become a leading digital biopharmaceutical company that delivers life-transforming treatments.”
Masato Iwasaki, Representative Director, Japan General Affairs will retire from the Board on the same day.
About Miki Tsusaka
Miki Tsusaka started his career at Takeda in 1985, in sales and marketing in Japan. He was later appointed Head of the Strategic Product Planning Department in 2008 and then became Head of the Pharmaceutical Marketing Division and Director in 2012. He served as President of the Japan Pharma Business Unit, a member of the Takeda Executive Team, from 2014, and assumed Japan General Affairs in 2021 to oversee overall business activities in Japan. Milano Furuta, who is currently President of Japan Pharma Business Unit will be named Japan Country Head in addition to his current role.
Miki Tsusaka is the current President of Microsoft Japan, appointed in February 2023. Before this role, Ms. Tsusaka was a Senior Partner and Managing Director at Boston Consulting Group, where she helped various industries with growth strategies, profitability, and digital transformation. At BCG, she established strategic consulting groups, specializing in marketing, sales, and pricing strategy development, served as CMO, and was a member of the Executive Committee for two three-year terms.
Ms. Tsusaka holds a Bachelor of Arts in Government and East Asian Studies from Harvard University and an MBA from the Harvard Business School.
Ms. Tsusaka said “I am honored to be a candidate to join Takeda’s Board of Directors. With my deep respect for Takeda’s strong leadership in biopharmaceutical science, values-based culture, and sustainability, I look forward to working alongside the rest of the Board to help deliver on Takeda’s purpose and vision.”
About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people, and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics, and Hematology, Neuroscience, and Gastroenterology, with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We focus on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving the quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
Source: https://www.takeda.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.